--- title: "Xencor | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 51.22 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/295005826.md" datetime: "2026-08-05T20:03:31.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/295005826.md) - [en](https://longbridge.com/en/news/295005826.md) - [zh-HK](https://longbridge.com/zh-HK/news/295005826.md) generator: "portal-rs" --- # Xencor | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 51.22 M Revenue: As of FY2026 Q2, the actual value is USD 51.22 M, beating the estimate of USD 18.92 M. EPS: As of FY2026 Q2, the actual value is USD -0.29, beating the estimate of USD -0.7975. EBIT: As of FY2026 Q2, the actual value is USD -21.92 M. ### Financial Performance for Second Quarter Ended June 30, 2026 #### Revenue Revenue for the second quarter of 2026 was $51.2 million, an increase of $7.6 million compared to $43.6 million for the same period in 2025. This revenue was primarily driven by milestone revenue from Zenas BioPharma and royalty revenue from Alexion and Incyte. Xencor, Inc. recognized $27.6 million in royalty revenue from U.S. Ultomiris sales during the dispute period in the second quarter of 2026. An additional $77.4 million of settlement consideration is expected to be recognized in the third quarter of 2026. #### Operating Expenses Research and development (R&D) expenses increased to $71.9 million in the second quarter of 2026, up from $61.7 million in the same period of 2025, primarily due to increased spending on pipeline programs, partially offset by lower stock-based compensation. General and administrative (G&A) expenses were $16.4 million in the second quarter of 2026, compared to $15.1 million in the second quarter of 2025, remaining relatively consistent. Total operating expenses for the second quarter of 2026 were $88.3 million, compared to $76.8 million for the same period in 2025. #### Operating Loss The operating loss for the second quarter of 2026 was - $37.1 million, compared to - $33.2 million for the second quarter of 2025. #### Other Income, Net Other income, net, significantly increased to $15.1 million in the second quarter of 2026, from $2.1 million in the same period of 2025, primarily due to unrealized gains on an equity security. #### Net Loss Attributable to Xencor, Inc. Net loss attributable to Xencor, Inc. was - $21.7 million for the second quarter of 2026, an improvement from - $30.8 million in the second quarter of 2025. ### Financial Performance for Six Months Ended June 30, 2026 #### Revenue Total revenue for the six months ended June 30, 2026, was $55.7 million, down from $76.3 million for the same period in 2025. #### Operating Expenses Research and development (R&D) expenses for the six months ended June 30, 2026, were $136.6 million, an increase from $120.2 million in the prior year. General and administrative (G&A) expenses were $34.1 million, compared to $32.5 million for the same period in 2025. Total operating expenses for the six-month period were $170.7 million, up from $152.7 million in 2025. #### Operating Loss The operating loss for the six months ended June 30, 2026, was - $114.9 million, compared to - $76.4 million for the same period in 2025. #### Total Other Income (Expense) Total other income (expense) was - $35.6 million for the six months ended June 30, 2026, compared to - $3.0 million in 2025. #### Net Loss Attributable to Xencor, Inc. Net loss attributable to Xencor, Inc. for the six months ended June 30, 2026, was - $150.6 million, compared to - $79.2 million for the same period in 2025. ### Cash and Marketable Securities Cash, cash equivalents, and marketable debt securities totaled $486.4 million as of June 30, 2026, a decrease from $610.8 million as of December 31, 2025. ### Unique Metrics and Partnership Developments Xencor, Inc. will receive $105 million from Alexion as a settlement for U.S. Ultomiris royalties, with payments expected in August 2026 and one year later. The company received a $10 million regulatory milestone payment from Zenas BioPharma in June 2026 following Zenas’s BLA submission for obexelimab, with potential for up to $450 million in future milestones and tiered royalties. ### Outlook and Guidance Xencor, Inc. projects to conclude 2026 with cash, cash equivalents, and marketable debt securities ranging between $420 million and $440 million. These financial resources are expected to be sufficient to fund its research and development programs and operations through 2028. ### Related Stocks - [XNCR.US](https://longbridge.com/en/quote/XNCR.US.md) ## Related News & Research - [Xencor to present at Cantor Global Healthcare Conference](https://longbridge.com/en/news/297823087.md) - [Legal & General Group Plc Acquires Shares of 1,091,177 Xencor, Inc. $XNCR](https://longbridge.com/en/news/297489574.md) - [Biopharma firm Xencor's Q2 revenue beats on royalty revenue, milestone payments](https://longbridge.com/en/news/295007889.md) - [Wedbush Reaffirms Their Buy Rating on Xencor (XNCR)](https://longbridge.com/en/news/293429610.md) - [JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Xencor (NASDAQ:XNCR) Stock](https://longbridge.com/en/news/297960898.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**